Welcome to our dedicated page for ESTABLISHMENT LABS HOLDINGS SEC filings (Ticker: ESTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Establishment Labs Holdings Inc. filings document regulatory disclosures for a British Virgin Islands medical technology issuer listed on Nasdaq. Its Form 8-K reports cover operating results and financial condition, preliminary financial information, Regulation FD presentation materials, credit-agreement amendments, senior secured term-loan obligations, and other material definitive agreements.
The company’s proxy materials disclose board matters, executive compensation, equity awards, shareholder voting items, and governance practices. Together, the filings describe the Motiva-focused breast aesthetics and reconstruction business, capital structure, debt arrangements, forward-looking-statement disclosures, and recurring corporate reporting obligations.
ESTABLISHMENT LABS HOLDINGS INC. (ESTA) reported an insider equity transaction by Chief Executive Officer and director Filippo Caldini. On 2026-08-20, 682 Common Shares were withheld by the company to cover tax withholding obligations arising from the vesting of previously granted restricted stock units. This was reported as a code F transaction (payment of tax liability by delivering or withholding securities), and Caldini’s directly held position after this withholding was 48,829 Common Shares.
Establishment Labs Holdings Inc., a medical device company focused on Motiva silicone breast implants, reported strong top-line growth while remaining unprofitable for the period ended June 30, 2026. Revenue reached $67.5 million in the quarter and $127.4 million for the first half of 2026, up 31.7% and 37.5%, respectively, versus 2025. Growth was driven mainly by the U.S. launch, with U.S. sales rising sharply and a more favorable geographic and product mix lifting gross margin to 70.6% in Q2 and 70.7% year-to-date.
Operating loss narrowed to $4.3 million in Q2 and $10.8 million for the first half, while net loss improved to $11.7 million in Q2 and $25.1 million year-to-date, or $0.39 and $0.84 per share. Operating cash outflow improved but remained negative at $20.9 million for the first half. Cash stood at $71.2 million and accumulated deficit at $520.9 million, with shareholders’ equity of $21.6 million. The company refinanced and upsized its Oaktree term loan into a new facility of up to $300 million, with $265 million funded and no principal due until 2031, increasing outstanding debt to $271.6 million. Management states it is in compliance with debt covenants and believes existing cash and cash generation can cover at least the next 12 months, while it continues to pursue patent litigation in multiple jurisdictions with outcomes not yet determinable.
Establishment Labs Holdings Inc. reported strong second-quarter 2026 growth, with revenue of $67.5 million, up 31.7% year over year and 12.8% sequentially. Motiva USA revenue rose to $24.7 million from $10.3 million a year earlier, and minimally invasive revenue reached $12.1 million. Gross margin improved to 70.6% from 68.8%, helped by higher-margin U.S. sales and its minimally invasive platform.
Loss from operations narrowed to $4.3 million from $14.1 million, and net loss improved to $11.7 million, or $0.39 per share. Adjusted EBITDA turned positive at $3.7 million versus a loss of $8.5 million in 2025. Cash and cash equivalents were $71.2 million as of June 30, 2026. Reflecting this performance, full-year 2026 revenue guidance was raised to $269–$271 million, up from $266.5–$268.5 million.
Establishment Labs Holdings, Inc. has a significant shareholder group led by JW Asset Management, LLC and related entities, which collectively report beneficial ownership of 2,692,856 common shares. These shares represent 9.15% of the outstanding common stock, based on 29,430,390 shares outstanding as of May 7, 2026, as referenced from the issuer’s quarterly report.
JW Asset Management, LLC, JW GP, LLC, and Jason G. Wild each report shared voting and dispositive power over 2,692,856 shares, while JW Partners reports 2,006,252 shares (6.82%) and JW Opportunities Fund, LLC reports 686,604 shares (2.33%). All reporting persons list 0 shares with sole voting or dispositive power, indicating that voting and disposition authority is shared for these positions.
BlackRock, Inc. reported beneficial ownership of common stock of Establishment Labs Inc. BlackRock and certain of its business units collectively beneficially own 1,576,071 shares of common stock, representing 5.4% of the class as of June 30, 2026.
BlackRock has sole voting power over 1,535,124 shares and sole dispositive power over 1,576,071 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no individual client holds more than five percent of the outstanding common shares.
Chacon Quiros Juan Jose reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros received a grant of 11,315 Common Shares as a stock unit award under the company’s 2018 Equity Incentive Plan, at a stated price of $0.0000 per share. One-fourth of the shares subject to the award vest on April 24, 2027 and on each one-year anniversary thereafter, contingent on continued service. Following this grant, he holds 56,508 Common Shares directly and 927,504 Common Shares indirectly through Sariel Group Ltd, where he has voting and dispositive power but disclaims beneficial ownership beyond his pecuniary interest.
ESTABLISHMENT LABS HOLDINGS INC. director Nicholas Sheridan Lewin received a grant of stock options covering 19,561 common shares at an exercise price of $66.28 per share, expiring on April 24, 2036. One-fourth of these options vest on April 24, 2027 and on each one-year anniversary thereafter, subject to continued service. Following the transactions, he held 1,079,960 common shares directly and 19,090 common shares indirectly through his spouse, plus the newly granted options.
Harris Taylor C. reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Harris Taylor C. received two equity awards in the form of stock units representing common shares. One grant covers 1,773 common shares, and another covers 1,949 common shares, both awarded at no cash cost as director compensation under the company’s 2018 Equity Incentive Plan.
The 1,773-share award vests in three equal annual installments on each yearly anniversary of the grant date, subject to continued service. The 1,949-share award vests in full on the earlier of June 24, 2027 or the day before the next annual stockholder meeting, also contingent on ongoing service.
Gillin Leslie reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Leslie Gillin received 196 common shares as a stock grant on June 30, 2026. The shares were elected in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy and issued under the 2018 Equity Incentive Plan, based on a closing price of $85.81 per share. Following this compensation-related award, Gillin directly holds 18,594 common shares.
Custin Ann reported acquisition or exercise transactions in this Form 4 filing.
Establishment Labs Holdings Inc. director Ann Custin received an equity grant of common shares as part of her board compensation. She was awarded 239 common shares, elected in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy. The shares were issued under the 2018 Equity Incentive Plan at a reference price of $85.81 per share, based on the closing price on the last trading day of the quarter. Following this grant, Custin directly holds 24,325 common shares of the company.